Cargando…

Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer–BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece

The aim of our study was to assess the immunogenicity of the third dose of the BNT162b2 mRNA COVID-19 vaccine (Comirnaty) in a cohort of 129 health-care workers in Greece whose anti-S1 RBD IgG titers were monitored over the course of nine months. Titers were measured for each participant just before...

Descripción completa

Detalles Bibliográficos
Autores principales: Kontopoulou, Konstantina, Nakas, Christos T., Papazisis, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228774/
https://www.ncbi.nlm.nih.gov/pubmed/35746484
http://dx.doi.org/10.3390/vaccines10060876
_version_ 1784734563338027008
author Kontopoulou, Konstantina
Nakas, Christos T.
Papazisis, Georgios
author_facet Kontopoulou, Konstantina
Nakas, Christos T.
Papazisis, Georgios
author_sort Kontopoulou, Konstantina
collection PubMed
description The aim of our study was to assess the immunogenicity of the third dose of the BNT162b2 mRNA COVID-19 vaccine (Comirnaty) in a cohort of 129 health-care workers in Greece whose anti-S1 RBD IgG titers were monitored over the course of nine months. Titers were measured for each participant just before the third dose (nine months after the second dose) and also one month after the third dose. Of the 129 participants, 19 had been previously infected before starting the vaccination scheme. The SARS-CoV-2 IgG II Quant assay on the Architect System was employed to longitudinally assess the titers of IgG against the receptor-binding domain of the S1 subunit of the spike protein (anti-S1 RBD). Boosters raised Geometric Mean Concentrations (GMCs) by a factor of approximately 47 relative to levels at 9 months and by a factor of approximately 23 relative to levels at 6 months. The immune response one month after the third dose was significantly higher than the response achieved one month after the second dose (p = 0.008). In conclusion, our findings verify the potent immunogenicity elicited by the third dose in all age and prior COVID-19 status groups, suggesting that the timely administration of the third (booster) dose maximizes the immunogenic potential of the vaccine.
format Online
Article
Text
id pubmed-9228774
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92287742022-06-25 Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer–BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece Kontopoulou, Konstantina Nakas, Christos T. Papazisis, Georgios Vaccines (Basel) Article The aim of our study was to assess the immunogenicity of the third dose of the BNT162b2 mRNA COVID-19 vaccine (Comirnaty) in a cohort of 129 health-care workers in Greece whose anti-S1 RBD IgG titers were monitored over the course of nine months. Titers were measured for each participant just before the third dose (nine months after the second dose) and also one month after the third dose. Of the 129 participants, 19 had been previously infected before starting the vaccination scheme. The SARS-CoV-2 IgG II Quant assay on the Architect System was employed to longitudinally assess the titers of IgG against the receptor-binding domain of the S1 subunit of the spike protein (anti-S1 RBD). Boosters raised Geometric Mean Concentrations (GMCs) by a factor of approximately 47 relative to levels at 9 months and by a factor of approximately 23 relative to levels at 6 months. The immune response one month after the third dose was significantly higher than the response achieved one month after the second dose (p = 0.008). In conclusion, our findings verify the potent immunogenicity elicited by the third dose in all age and prior COVID-19 status groups, suggesting that the timely administration of the third (booster) dose maximizes the immunogenic potential of the vaccine. MDPI 2022-05-30 /pmc/articles/PMC9228774/ /pubmed/35746484 http://dx.doi.org/10.3390/vaccines10060876 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kontopoulou, Konstantina
Nakas, Christos T.
Papazisis, Georgios
Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer–BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece
title Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer–BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece
title_full Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer–BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece
title_fullStr Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer–BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece
title_full_unstemmed Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer–BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece
title_short Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer–BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece
title_sort significant increase in antibody titers after the 3rd booster dose of the pfizer–biontech mrna covid-19 vaccine in healthcare workers in greece
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228774/
https://www.ncbi.nlm.nih.gov/pubmed/35746484
http://dx.doi.org/10.3390/vaccines10060876
work_keys_str_mv AT kontopouloukonstantina significantincreaseinantibodytitersafterthe3rdboosterdoseofthepfizerbiontechmrnacovid19vaccineinhealthcareworkersingreece
AT nakaschristost significantincreaseinantibodytitersafterthe3rdboosterdoseofthepfizerbiontechmrnacovid19vaccineinhealthcareworkersingreece
AT papazisisgeorgios significantincreaseinantibodytitersafterthe3rdboosterdoseofthepfizerbiontechmrnacovid19vaccineinhealthcareworkersingreece